Epilogue: The future of Laron syndrome — The need for changes

https://doi.org/10.1016/j.ghir.2015.07.007Get rights and content

Highlights

  • Advocacy and education will lead to early diagnosis of Laron Syndrome

  • The clinical grade IGF-1, the only treatment for Laron syndrome patients, is unavailable to many of the patients due to lack of appropriate health insurance systems for orphan diseases.

  • Without hope of treatment many Laron syndrome children remain undiagnosed.

Section snippets

Conflict of interest

No conflict of interest.

References (7)

  • R. Steuerman et al.

    Congenital IGF-I deficiency tends to confer protection against postnatal development of malignancies

    Eur. J. Endocrinol.

    (2011)
  • F.T. Gonçalves et al.

    The E180splice Mutation in the GHR gene causing Laron syndrome: witness of a Sephardic Jewish Exodus from the Iberian Peninsula to the New World?

    Am. J. Med. Genet.

    (2014)
  • Z. Laron

    Emerging treatment options for patients with Laron syndrome

    Expert Opin. Orphan Drugs.

    (2014)
There are more references available in the full text version of this article.

Cited by (7)

  • Growth hormone receptor-deficient pigs resemble the pathophysiology of human Laron syndrome and reveal altered activation of signaling cascades in the liver

    2018, Molecular Metabolism
    Citation Excerpt :

    As a consequence, LS patients have low levels of insulin-like growth factor 1 (IGF1) and – due to the lack of feedback inhibition of GH secretion – high levels of GH [3]. A few hundred cases of LS have been reported world-wide, caused by a variety of GHR mutations (reviewed in [4]). Among them is an isolated, more homogeneous population of GHR deficient patients in Ecuador with only two distinct mutations of the GHR gene [5–7].

View all citing articles on Scopus
View full text